Methylone (3,4-methylenedioxy-N-methylcathinone) is a synthetic cathinone analog of the recreational drug ecstasy. Although it is marketed to recreational users as relatively safe, fatalities due to hyperthermia, serotonin syndrome, and multi-organ system failure have been reported. Since psychopharmacological data remain scarce, we have focused our research on pharmacokinetics, and on a detailed evaluation of temporal effects of methylone and its metabolite nor-methylone on behavior and body temperature in rats. Methylone [5, 10, 20, and 40 mg/kg subcutaneously (s.c.)] and nor-methylone (10 mg/kg s.c.) were used in adolescent male Wistar rats across three behavioral/physiological procedures and in two temporal windows from administration (15 and 60 min) in order to test: locomotor effects in the open field, sensorimotor gating in the test of prepulse inhibition (PPI), and effects on rectal temperature in individually and group-housed rats. Serum and brain pharmacokinetics after 10 mg/kg s.c. over 8 h were analyzed using liquid chromatography mass spectrometry. Serum and brain levels of methylone and nor-methylone peaked at 30 min after administration, both drugs readily penetrated the brain with serum: brain ratio 1:7.97. Methylone dose-dependently increased overall locomotion. It also decrease the amount of time spent in the center of open field arena in dose 20 mg/kg and additionally this dose induced stereotyped circling around the arena walls. The maximum of effects corresponded to the peak of its brain concentrations. Nor-methylone had approximately the same behavioral potency. Methylone also has weak potency to disturb PPI. Behavioral testing was not performed with 40 mg/kg, because it was surprisingly lethal to some animals. Methylone 10 and 20 mg/kg s.c. induced hyperthermic reaction which was more pronounced in group-housed condition relative to individually housed rats. To conclude, methylone increased exploration and/or decreased anxiety in the open field arena and with nor-methylone had short duration of action with effects typical for mixed indirect dopamine-serotonin agonists such as 3,4-metyhlenedioxymethamphetamine (MDMA) or amphetamine. Given the fact that the toxicity was even higher than the known for MDMA and that it can cause hyperthermia it possess a threat to users with the risk for serotonin syndrome especially when used in crowded conditions.

1st Faculty of Medicine Institute of Forensic Medicine and Toxicology Charles University and General University Hospital Prague Prague Czechia

3rd Faculty of Medicine Charles University Prague Prague Czechia

Department of Experimental Neurobiology National Institute of Mental Health Klecany Czechia

Department of Physiology Faculty of Science Charles University Prague Czechia

Forensic Laboratory of Biologically Active Compounds Department of Chemistry of Natural Compounds University of Chemistry and Technology Prague Prague Czechia

Zobrazit více v PubMed

Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol (2012) 8:33–42.10.1007/s13181-011-0193-z PubMed DOI PMC

Jacob P, Shulgin AT, Inventors; Neurobiological Technologies, Inc., Preparation of Novel N-Substituted-2-Amino-3’,4’-Methylenedioxy Propiophenone As Anti-Depressant and Anti-Parkinsonism Agents. US Patent WO9639133 (1996).

Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly (2015) 145:w14043.10.4414/smw.2015.14043 PubMed DOI

Bossong MG, Van Dijk JP, Niesink RJM. Methylone and mCPP, two new drugs of abuse? Addict Biol (2005) 10:321–3.10.1080/13556210500350794 PubMed DOI

Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (2011) 49:499–505.10.3109/15563650.2011.590812 PubMed DOI

EMCDDA. Annual Report: The State of the Drugs Problem in Europe. Lisbon: (2006).

Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final order. Fed Regist (2011) 76:65371–75. PubMed

Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC, Garg U, et al. Three fatal intoxications due to methylone. J Anal Toxicol (2012) 36:444–51.10.1093/jat/bks043 PubMed DOI

Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C. Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol (2012) 8:65–8.10.1007/s13181-011-0199-6 PubMed DOI PMC

Cozzi NV, Sievert MK, Shulgin AT, Jacob P, Ruoho AE. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol (1999) 381:63–9.10.1016/S0014-2999(99)00538-5 PubMed DOI

Nagai F, Nonaka R, Kamimura KSH. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol (2007) 559:132–7.10.1016/j.ejphar.2006.11.075 PubMed DOI

Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol (2013) 168:458–70.10.1111/j.1476-5381.2012.02145.x PubMed DOI PMC

Miyazawa M, Kojima T, Nakaji S. Behavioral and rewarding effects of methylone, an analog of MDMA in mice. Hirosaki Med J (2011) 62:56–71.

Watterson LR, Hood L, Sewalia K, Tomek SE, Yahn S, Johnson CT, et al. The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in “bath salts”. J Addict Res Ther (2012) (Suppl 9):18.10.4172/2155-6105.S9-002 PubMed DOI PMC

DalCason TA, Young R, Glennon RA. Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav (1997) 58:1109–16.10.1016/S0091-3057(97)00323-7 PubMed DOI

Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J. Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol (2012) 167:407–20.10.1111/j.1476-5381.2012.01998.x PubMed DOI PMC

Marusich JA, Grant KR, Blough BE, Wiley JL. Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology (2012) 33:1305–13.10.1016/j.neuro.2012.08.003 PubMed DOI PMC

Gatch MB, Taylor CM, Forster MJ. Locomotor stimulant and discriminative stimulus effects of ‘bath salt’ cathinones. Behav Pharmacol (2013) 24:437–47.10.1097/FBP.0b013e328364166d PubMed DOI PMC

Javadi-Paydar M, Nguyen JD, Vandewater SA, Dickerson TJ, Taffe MA. Locomotor and reinforcing effects of pentedrone, pentylone and methylone. Neuropharmacology (2017):1–8.10.1016/j.neuropharm.2017.09.002 PubMed DOI PMC

Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci (1998) 18:5086–94. PubMed PMC

Palenicek T, Balikova M, Rohanova M, Novak T, Horacek J, Fujakova M, et al. Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats. Pharmacol Biochem Behav (2011) 98:130–9.10.1016/j.pbb.2010.12.011 PubMed DOI

Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology (2012) 37:1192–203.10.1038/npp.2011.304 PubMed DOI PMC

Pedersen AJ, Petersen TH, Linnet K. In vitro metabolism and pharmacokinetic studies on methylone. Drug Metab Dispos (2013) 41:1247–55.10.1124/dmd.112.050880 PubMed DOI

Zidkova M, Linhart I, Balikova M, Himl M, Dvorackova V, Lhotkova E, et al. Identification of three new phase II metabolites of a designer drug methylone formed in rats by N-demethylation followed by conjugation with dicarboxylic acids. Xenobiotica (2017):1–8.10.1080/00498254.2017.1349964 PubMed DOI

Palenicek T, Hlinak Z, Bubenikova-Valesova V, Votava M, Horacek J. An analysis of spontaneous behavior following acute MDMA treatment in male and female rats. Neuro Endocrinol Lett (2007) 28:781–8. PubMed

Horsley RR, Lhotkova E, Hajkova K, Jurasek B, Kuchar M, Palenicek T. Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—behavioural, pharmacokinetic and metabolic studies in the Wistar rat. Brain Res Bull (2016) 126:102–10.10.1016/j.brainresbull.2016.05.002 PubMed DOI

Palenicek T, Lhotkova E, Zidkova M, Balikova M, Kuchar M, Himl M, et al. Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): pharmacokinetics, behaviour, thermoregulation and LD50 in rats. Prog Neuropsychopharmacol Biol Psychiatry (2016) 69:49–59.10.1016/j.pnpbp.2016.04.004 PubMed DOI

Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol (2000) 11:185–204.10.1097/00008877-200006000-00002 PubMed DOI

Bubenikova V, Votava M, Horacek J, Palenicek T. Relation of sex and estrous phase to deficits in prepulse inhibition of the startle response induced by ecstasy (MDMA). Behav Pharmacol (2005) 16:127–30.10.1097/00008877-200503000-00009 PubMed DOI

Palenicek T, Votava M, Bubenikova V, Horacek J. Increased sensitivity to the acute effects of MDMA (“ecstasy”) in female rats. Physiol Behav (2005) 86:546–53.10.1016/j.physbeh.2005.08.043 PubMed DOI

Palenicek T, Fujakova M, Brunovsky M, Horacek J, Gorman I, Balikova M, et al. Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology (2013) 225:75–93.10.1007/s00213-012-2797-7 PubMed DOI

Elmore JS, Dillon-Carter O, Partilla JS, Ellefsen KN, Concheiro M, Suzuki M, et al. Pharmacokinetic profiles and pharmacodynamic effects for methylone and its metabolites in rats. Neuropsychopharmacology (2017) 42(3):649–60.10.1038/npp.2016.213 PubMed DOI PMC

Lopez-Arnau R, Martinez-Clemente J, Carbo ML, Pubill D, Escubedo E, Camarasa J. An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts”. Prog Neuropsychopharmacol Biol Psychiatry (2013) 45:64–72.10.1016/j.pnpbp.2013.04.007 PubMed DOI

Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica (2006) 36:709–23.10.1080/00498250600780191 PubMed DOI

Ellefsen KN, Concheiro M, Suzuki M, Rice KC, Elmore JS, Baumann MH, et al. Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. Foren Toxicol (2015) 33:202–12.10.1007/s11419-015-0263-z DOI

Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, Rothman RB, Huestis MA. Effects of dose and route of administration on pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos (2009) 37:2163–70.10.1124/dmd.109.028506 PubMed DOI PMC

Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA. Nonlinear pharmacokinetics of (±)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos (2014) 42:119–25.10.1124/dmd.113.053678 PubMed DOI PMC

Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med (2005) 352:1112–20.10.1056/NEJMra041867 PubMed DOI

McNamara RK, Logue A, Stanford K, Xu M, Zhang J, Richtand NM. Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse (2006) 60:399–405.10.1002/syn.20315 PubMed DOI PMC

Gregg RA, Rawls SM. Behavioral pharmacology of designer cathinones: a review of the preclinical literature. Life Sci (2014) 97:27–30.10.1016/j.lfs.2013.10.033 PubMed DOI PMC

Chitty K, Albrecht MA, Graham K, Kerr C, Lee JWY, Iyyalol R, et al. Dexamphetamine effects on prepulse inhibition (PPI) and startle in healthy volunteers. Psychopharmacology (2014) 231:2327–37.10.1007/s00213-013-3395-z PubMed DOI

Vollenweider FX, Remensberger S, Hell D, Geyer MA. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology (1999) 143:365–72.10.1007/s002130050960 PubMed DOI

Den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpi ER. Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone. Pharmacol Biochem Behav (2013) 103:501–9.10.1016/j.pbb.2012.10.006 PubMed DOI

Piao YS, Hall FS, Moriya Y, Ito M, Ohara A, Kikura-Hanajiri R, et al. Methylone-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Behav Pharmacol (2015) 26:345–52.10.1097/FBP.0000000000000135 PubMed DOI

Green AR, O’Shea E, Colado MI. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol (2004) 500:3–13.10.1016/j.ejphar.2004.07.006 PubMed DOI

Jaehne EJ, Salem A, Irvine RJ. Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation. Pharmacol Biochem Behav (2005) 81:485–96.10.1016/j.pbb.2005.04.005 PubMed DOI

Herin DV, Liu SJ, Urich T, Rice KC, Cunningham KA. Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (2005) 178:505–13.10.1007/s00213-004-2030-4 PubMed DOI

Shortall SE, Green AR, Swift KM, Fone KCF, King MV. Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. Br J Pharmacol (2013) 168:966–77.10.1111/j.1476-5381.2012.02236.x PubMed DOI PMC

Shortall SE, Green AR, Fone KC, King MV. Caffeine alters the behavioural and body temperature responses to mephedrone without causing long-term neurotoxicity in rats. J Psychopharmacol (2016) 30:698–706.10.1177/0269881116650408 PubMed DOI

Aguirre N, Ballaz S, Lasheras B, Del Rio J. MDMA (‘ecstasy’) enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol (1998) 346:181–8.10.1016/S0014-2999(98)00062-4 PubMed DOI

Brown PL, Kiyatkin EA. Brain hyperthermia induced by MDMA (‘ecstasy’): modulation by environmental conditions. Eur J Neurosci (2004) 20:51–8.10.1111/j.0953-816X.2004.03453.x PubMed DOI

Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation

Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ9-THC in Rats

Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat

Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats